United Kingdom

People: Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

25 Apr 2019
Change (% chg)

$0.31 (+3.24%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Hutt, Peter 

Mr. Peter Barton Hutt is the Director of Concert Pharmaceuticals Inc. Mr. Hutt has served as a member of our board of directors since December 2006Mr. Hutt has practiced law at Covington & Burling LLP, specializing in food and drug law, since 1960 (except for the period from 1971 to 1975) and currently serves as senior counsel. From 1971 to 1975 he was Chief Counsel for the Food and Drug Administration. Mr. Hutt is a member of the board of directors of Flex Pharma, Inc., BIND Therapeutics, Inc., DBV Technologies SA, Q Therapeutics, Inc. and Xoma Ltd., each of which is a public biotechnology company, as well as numerous private companies. During the last five years, Mr. Hutt also served as a member of the board of directors of Celera Genomics, a public biotechnology company that was acquired by Quest Diagnostics, Inc. in 2011 and Momenta Pharmaceuticals, Inc., a biotechnology company. Mr. Hutt received a B.A. from Yale University, an LL.B. from Harvard Law School and an LL.M. from New York University School of Law. We believe Mr. Hutt’s extensive knowledge of regulatory and legal issues related to drug development and his service on numerous boards of directors allows him to be a key contributor to our board of directors.

Basic Compensation

Total Annual Compensation, USD 29,970
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 90,720
Fiscal Year Total, USD 120,690

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Aldrich


Roger Tung


Marc Becker


Nancy Stuart


Lynette Herscha


James Cassella,

As Of  31 Dec 2017